Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function

Area of Science:

• Respiratory Medicine
• Biomarkers
• Pulmonary Physiology

Background:

• Exhaled nitric oxide (eNO) is a marker of airway inflammation.
• Chronic Obstructive Pulmonary Disease (COPD) and asthma are distinct inflammatory airway diseases.
• Understanding eNO in COPD is crucial for diagnosis and management.

Purpose of the Study:

• Compare eNO levels in former smokers with COPD, asthma patients, and healthy volunteers.
• Investigate the relationship between eNO and lung function in COPD.
• Examine the impact of inhaled corticosteroid (ICS) use on eNO in COPD and asthma.

Main Methods:

• Measured eNO, spirometry, lung volumes, DL,CO, and Sa,O2 in three groups: former smokers with COPD, asthma patients, and healthy non-smokers.
• Analyzed correlations between eNO and lung function parameters.
• Compared eNO levels based on ICS use within COPD and asthma cohorts.

Main Results:

• Median eNO was higher in COPD than healthy volunteers (p=0.003) but lower than in asthma (p<0.01).
• No significant difference in eNO was observed between COPD patients with or without ICS use.
• Asthma patients using ICS had lower eNO than those not using ICS (p=0.034).
• In COPD, eNO inversely correlated with FEV1, DL,CO, Sa,O2, and positively with RV/TLC ratio.

Conclusions:

• Exhaled nitric oxide is elevated in COPD, influenced by tobacco-induced lung damage.
• eNO serves as a potential biomarker reflecting disease severity and structural changes in COPD.
• ICS impact eNO in asthma but not in COPD, suggesting different inflammatory pathways.